Medications Maintenance therapy with rucaparib shows clinical responses in a subgroup of patients with pancreatic cancer 04/02/2019 Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy, Read More